0 Replies
WORCESTER, Mass., Jan 19, 2010 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia’s RNA Silencing: Mechanism, Biology and... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Jan 14, 2010 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced a collaboration with Shalesh Kaushal, M.D., Ph.D., Chairman of the Department of Ophthalmology at The University of Massachusetts Medical... Contine Reading & Discuss→
0 Replies
BOULDER, Colo., January 11, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Jan 07, 2010 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the Biotech... Contine Reading & Discuss→
